The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
40
No.
08
February 21, 2014
- NCI Launches M-PACT Next-Generation Trial As Group System Nears March 1 Transition
- NCI Clinical Trials Enrollment Drops to 17,500
- GAO: FDA Data On Drug Shortages Inadequate
- Duke’s Victor Dzau Named President of The Institute of Medicine
- In Brief: NCI’s John Czajkowski Takes Executive Dean Position At Harvard Medical School
CCL
Vol.
37
No.
2
February 28, 2014
- Phase III Avastin Trial Fails Primary Endpoints
- Preventive Ovarian Surgery Recommended For Women with BRCA1 Mutations by Age 35
- Two Studies Suggest Positive HPV Status Can Indicate Improved Patient Outcomes
- Lymphatic Mapping Techniques Can Outperform “Watch-and-Wait”
- Study Shows MammaPrint Test Can Predict 25-Year Risk Levels
- Study: Women at Higher Risk Of Estrogen Receptor Positive Breast Cancer After Smoking
- NIH Study Confirms Male Risk Factors For Breast Cancer
- Lateral Radiation Therapy Results in Regional Control In Advanced Tonsil Cancer
- Daily Humidification Improves Quality-of-Life in Phase III Trial
- Five Years after Proton Therapy, 75-99% of Men Live Cancer-Free
- Study: Prostate Cancer Classifier Can Predict Risk Better Than PSA, Gleason Score, Tumor Stage
- Daily Aspirin May Reduce Risk By 20 Percent, Study Says
- NCI CTEP-Approved Trials For the Month of February
- CHMP Delivers Positive Opinion For Two-Dose HPV Vaccine
TCL
Vol.
40
No.
10
March 07, 2014
- NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level
- President Requests Extra $200 Million For NIH
- HPV Vaccines Should Be Priority, Say President’s Cancer Panel
- NCI Publishes Report On Pancreatic Cancer
- In Brief: Pasche Named Director of Wake Forest Cancer Center
TCL
Vol.
40
No.
11
March 14, 2014
CCL
Vol.
37
No.
3
March 28, 2014
- Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors
- Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial
- IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC
- Study: End-of-Life Chemotherapy Leads to More Deaths in Hospital
- Y-90 Radioembolization Stabilizes Liver Metastases in 98.5 Percent Of Breast Cancer Patients in Study
- Study: Robotic-Assisted Surgery Offers Better Cancer Control
- Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival
- Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC
- NCI CTEP-Approved Trials For the Month of March
- European Commission Approves Subcutaneous Rituximab